The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The bleeding disorders community reminds me of that massive oak tree.

随着医疗科技的不断进步，新疗法层出不穷，特别是针对糖尿病和血友病等慢性病症的治疗手段日益多样化。而最近，来自药物研发领域的新闻，尤其是关于潜在重磅治疗方案的FDA批准，真的是引发了广泛关注！你想知道具体的详情吗？ 我们来看看近期一个备受 ...

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...